Leukemia stem cell targeting ligands and methods of use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10100083
APP PUB NO 20160237118A1
SERIAL NO

15142912

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Pan, Chong-xian Davis, US 13 17
Zhang, Hongyong Davis, US 462 30431

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 16, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 16, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00